|
US1019519A
(en)
|
1911-07-11 |
1912-03-05 |
Oscar Martin Polin |
Apparatus for making backing for teeth.
|
|
US4172896A
(en)
|
1978-06-05 |
1979-10-30 |
Dainippon Pharmaceutical Co., Ltd. |
Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
|
|
GB9217295D0
(en)
|
1992-08-14 |
1992-09-30 |
Wellcome Found |
Controlled released tablets
|
|
GB9315856D0
(en)
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
|
US5358970A
(en)
|
1993-08-12 |
1994-10-25 |
Burroughs Wellcome Co. |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
|
US5541231A
(en)
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
|
DE69839355T2
(de)
|
1997-07-29 |
2009-06-04 |
Alcon Laboratories, Inc., Fort Worth |
Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
|
|
AU2483599A
(en)
|
1998-01-29 |
1999-08-16 |
Sepracor, Inc. |
Pharmaceutical uses of optically pure (-)-bupropion
|
|
US8889112B2
(en)
|
1999-09-16 |
2014-11-18 |
Ocularis Pharma, Llc |
Ophthalmic formulations including selective alpha 1 antagonists
|
|
US6451828B1
(en)
|
2000-08-10 |
2002-09-17 |
Elan Pharmaceuticals, Inc. |
Selective inhibition of glutaminase by bis-thiadiazoles
|
|
AU2002305926A1
(en)
|
2001-02-05 |
2002-10-08 |
Exegenics Inc. |
Cysteine protease inhibitors
|
|
US7714139B2
(en)
*
|
2003-03-27 |
2010-05-11 |
Lankenau Institute For Medcial Research |
IDO inhibitors and methods of use
|
|
US6933289B2
(en)
|
2003-07-01 |
2005-08-23 |
Allergan, Inc. |
Inhibition of irritating side effects associated with use of a topical ophthalmic medication
|
|
EP1654002B2
(en)
|
2003-08-07 |
2014-01-29 |
Allergan, Inc. |
Compositions for delivery of therapeutics into the eyes
|
|
US20050059744A1
(en)
|
2003-09-12 |
2005-03-17 |
Allergan, Inc. |
Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
|
|
ES2367311T3
(es)
|
2004-04-15 |
2011-11-02 |
University Of Florida Research Foundation, Inc. |
Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
|
|
TW200911798A
(en)
|
2007-08-02 |
2009-03-16 |
Amgen Inc |
PI3 kinase modulators and methods of use
|
|
US10047066B2
(en)
*
|
2007-11-30 |
2018-08-14 |
Newlink Genetics Corporation |
IDO inhibitors
|
|
KR101325374B1
(ko)
|
2008-02-19 |
2013-11-08 |
가부시키가이샤 오츠까 세이야꾸 고죠 |
신체 기능의 회복에 유용한 경구 또는 경장 조성물
|
|
LT2389352T
(lt)
*
|
2009-01-26 |
2019-06-10 |
The Trustees Of The University Of Pennsylvania |
Arginazės inhibitoriai ir naudojimo būdai
|
|
WO2011143160A2
(en)
|
2010-05-10 |
2011-11-17 |
The Johns Hopkins University |
Metabolic inhibitor against tumors having an idh mutation
|
|
US10064885B2
(en)
|
2010-07-09 |
2018-09-04 |
Massachusetts Institute Of Technology |
Metabolic gene, enzyme, and flux targets for cancer therapy
|
|
WO2012068512A1
(en)
|
2010-11-18 |
2012-05-24 |
Deuteria Pharmaceuticals Llc |
3-deutero-pomalidomide
|
|
CA2824599C
(en)
*
|
2010-12-31 |
2020-03-10 |
Astrazeneca Uk Limited |
Arginase inhibitors and methods of use thereof
|
|
CA2742342A1
(en)
|
2011-02-12 |
2012-08-12 |
Baylor Research Institute |
Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
|
|
FI20115876A0
(fi)
|
2011-09-06 |
2011-09-06 |
Turun Yliopisto |
Yhdistelmähoito
|
|
CN103030597B
(zh)
|
2011-09-30 |
2014-10-01 |
南昌滨西科技有限公司 |
肾脏型谷氨酰胺酶抑制剂及其制备方法和用途
|
|
WO2013059437A1
(en)
*
|
2011-10-19 |
2013-04-25 |
Mars, Incorporated |
Inhibitors of arginase and their therapeutic applications
|
|
US8604016B2
(en)
|
2011-11-21 |
2013-12-10 |
Calithera Biosciences Inc. |
Heterocyclic inhibitors of glutaminase
|
|
HRP20192144T1
(hr)
*
|
2011-11-21 |
2020-02-21 |
Calithera Biosciences Inc. |
Heterociklični inhibitori glutaminaze
|
|
EP2855698A4
(en)
|
2012-05-24 |
2016-03-30 |
Dana Farber Cancer Inst Inc |
OBTAINING TO THE GLUTAMINE-TO-PYRUVAT SIGNAL PATH FOR THE TREATMENT OF CANCER ASSOCIATED WITH THE KRAS ONKOGEN
|
|
EP2892537A1
(en)
|
2012-09-10 |
2015-07-15 |
Celgene Corporation |
Methods for the treatment of locally advanced breast cancer
|
|
EP2895623B1
(en)
|
2012-09-17 |
2018-08-22 |
Agios Pharmaceuticals, Inc. |
Use of e-cadherin and vimentin for selection of treatment responsive patients
|
|
BR112015010955A2
(pt)
|
2012-11-16 |
2017-07-11 |
Calithera Biosciences Inc |
inibidores de glutaminase heterocíclica
|
|
MX369691B
(es)
|
2012-11-21 |
2019-11-19 |
Agios Pharmaceuticals Inc |
Inhibidores de glutaminasa y métodos de empleo.
|
|
WO2014079011A1
(en)
|
2012-11-22 |
2014-05-30 |
Agios Pharmaceuticals, Inc. |
Heterocyclic compounds for inhibiting glutaminase and their methods of use
|
|
CA2892817A1
(en)
*
|
2012-12-03 |
2014-06-12 |
Calithera Biosciences Inc. |
Treatment of cancer with heterocyclic inhibitors of glutaminase
|
|
EP2970114B1
(en)
*
|
2013-03-15 |
2019-05-15 |
Bristol-Myers Squibb Company |
Ido inhibitors
|
|
EA201690746A1
(ru)
*
|
2013-10-25 |
2016-12-30 |
Фармасайкликс Элэлси |
Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
|
|
WO2015061432A1
(en)
|
2013-10-25 |
2015-04-30 |
Calithera Biosciences, Inc. |
Treatment of viral infections with inhibitors of glutaminase
|
|
GB201322725D0
(en)
*
|
2013-12-20 |
2014-02-05 |
Immodulon Therapeutics Ltd |
Cancer therapy
|
|
WO2015125652A1
(ja)
*
|
2014-02-21 |
2015-08-27 |
Ｉｄａｃセラノスティクス株式会社 |
固形がんの治療剤
|
|
US20150258082A1
(en)
|
2014-03-14 |
2015-09-17 |
Francesco Parlati |
Combination therapy with glutaminase inhibitors
|
|
US10221459B2
(en)
|
2014-05-13 |
2019-03-05 |
Case Western Reserve University |
Compositions and methods of treating cancer harboring PIKC3A mutations
|
|
SG11201610333VA
(en)
|
2014-06-13 |
2017-01-27 |
Calithera Biosciences Inc |
Combination therapy with glutaminase inhibitors
|
|
WO2016004413A2
(en)
|
2014-07-03 |
2016-01-07 |
Board Of Regents, University Of Texas System |
Gls1 inhibitors for treating disease
|
|
WO2016004418A1
(en)
|
2014-07-03 |
2016-01-07 |
Board Of Regents, University Of Texas System |
Glutaminase inhibitor therapy
|
|
WO2016014890A1
(en)
*
|
2014-07-24 |
2016-01-28 |
Calithera Biosciences, Inc. |
Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
|
|
MX2017001620A
(es)
|
2014-08-07 |
2017-05-10 |
Calithera Biosciences Inc |
Formas cristalinas de inhibidores de glutaminasa.
|
|
WO2016054388A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Glutaminase inhibitors
|
|
WO2016077632A2
(en)
|
2014-11-13 |
2016-05-19 |
Buck Institute For Research On Aging |
Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
|
|
BR112017020780A2
(pt)
|
2015-03-30 |
2018-06-26 |
Calithera Biosciences Inc |
métodos de administração de inibidores de glutaminase
|
|
AU2016246521B2
(en)
|
2015-04-06 |
2020-07-09 |
Calithera Biosciences, Inc. |
Treatment of lung cancer with inhibitors of glutaminase
|
|
CN108135875B
(zh)
|
2015-07-31 |
2021-12-31 |
约翰霍普金斯大学 |
用于治疗代谢重编程病症的方法和组合物
|
|
US20190054090A1
(en)
|
2015-10-01 |
2019-02-21 |
Gilead Sciences, Inc. |
Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
|
|
EP3359150A4
(en)
|
2015-10-05 |
2019-11-06 |
Calithera Biosciences, Inc. |
COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGICAL AGENTS
|
|
LT3458053T
(lt)
|
2016-05-20 |
2022-02-25 |
Biohaven Pharmaceutical Holding Company Ltd. |
Riluzolo, rilizolo provaistų arba riluzolo analogų panaudojimas kartu su imunoterapijomis vėžio formų gydymui
|
|
US10195197B2
(en)
|
2016-08-25 |
2019-02-05 |
Calithera Biosciences, Inc. |
Combination therapy with glutaminase inhibitors
|
|
KR20190040302A
(ko)
|
2016-08-25 |
2019-04-17 |
칼리테라 바이오사이언시즈, 인코포레이티드 |
글루타미나제 억제제와의 병용 요법
|
|
WO2018039442A1
(en)
|
2016-08-25 |
2018-03-01 |
Calithera Biosciences, Inc. |
Treatment of cancer with inhibitors of glutaminase
|
|
US20200038398A1
(en)
|
2017-03-10 |
2020-02-06 |
Calithera Biosciences, Inc. |
Combination therapy with glutaminase inhibitors
|
|
US20210177841A1
(en)
*
|
2017-11-03 |
2021-06-17 |
Calithera Biosciences, Inc. |
Conjoint therapy with glutaminase inhibitors
|